Europska Unija - litavski - EMA (European Medicines Agency)

serb sas - glucarpidase - metabolic side effects of drugs and substances - visi kiti gydomieji produktai - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.

Litva - litavski - SMCA (Valstybinė vaistų kontrolės tarnyba)

vioser s.a. parenteral solutions industry - metronidazolas - infuzinis tirpalas - 500 mg/100 ml - metronidazole

Europska Unija - litavski - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - kiaulės - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Europska Unija - litavski - EMA (European Medicines Agency)

ceva santé animale - genetiškai modifikuotų rekombinantinis shiga toksiną-2e antigeno - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - kiaulės - veiklioji paršelių imunizacija nuo keturių dienų amžiaus, siekiant sumažinti escherichia coli (stec) gaminamo shiga toksino 2e sukeltos edemos ligos mirtingumą ir klinikinius požymius. imuniteto atsiradimas: 21 diena po vakcinacijos. imuniteto trukmė: 105 dienos po vakcinacijos.

Europska Unija - litavski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - kiaulės - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Europska Unija - litavski - EMA (European Medicines Agency)

belpharma s.a. - tasonerminas - sarkoma - immunostimulants, - beromun yra nurodyta, suaugusiems, kaip papildoma priemonė siekiant chirurgija vėliau pašalinamas navikas, siekiant išvengti arba atidėti amputacija, arba palaikomoji situacija, irresectable minkštųjų audinių sarkoma galūnių, naudojama kartu su melphalan per lengvas hyperthermic izoliuotos galūnės perfuzijos (ilp).

Europska Unija - litavski - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumianetą galima vartoti kaip monoterapiją arba kartu su metotreksatu. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Litva - litavski - SMCA (Valstybinė vaistų kontrolės tarnyba)

sopharma ad - diklofenako natrio druska - gelis - 10 mg/g - diclofenac

Litva - litavski - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz gmbh - ampicilinas - milteliai injekciniam ar infuziniam tirpalui - 500 mg; 1 g - ampicillin

Europska Unija - litavski - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - dantų atmetimas - imunosupresantai - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.